What Is the JIRE ETF? A Complete Guide to Returns, Expense Ratio, Holdings, and Alternative ETFs
The JPMorgan International Research Enhanced Equity ETF (JIRE) is an active ETF that invests in developed-market equities outside the US based on the MSCI EAFE index. It features a low expense ratio, quarterly dividends, and a beta-neutral design, with the comparison against passive alternatives such as VEA and IEFA serving as the key selection criterion.
What Is the JPMorgan International Research Enhanced Equity ETF?
It is an active ETF that uses the MSCI EAFE index—composed of large- and mid-cap stocks from developed markets excluding the US—as its benchmark. The structure combines passive index tracking with the manager's research, fine-tuning individual stock weights while maintaining risk characteristics similar to the index.
It is well suited for long-term investors seeking diversification across developed-market equities outside the US while aiming for a modest excess return versus the index.
The ETF is actively managed by J.P. Morgan Asset Management.
How Does the JPMorgan International Research Enhanced Equity ETF Invest?| Item | Details |
|---|---|
| Benchmark Index | MSCI EAFE |
| Management Style | Active (Research Enhanced) |
| Rebalancing Frequency | Ongoing (manager discretion) |
| Dividend Frequency | Quarterly |
| Manager | J.P. Morgan Asset Management |
| Total Expense Ratio | 0.24% |
Based on the MSCI EAFE index, the manager incorporates research views to slightly overweight or underweight individual stocks. At the same time, regional, sector, and style exposures are kept neutral relative to the index to manage tracking error at a low level while pursuing long-term excess returns.
- Research-driven stock adjustments that maintain index neutrality
- Risk management targeting a low tracking error
JPMorgan International Research Enhanced Equity ETF Size and Cost (AUM · Expense Ratio)
Assets under management (AUM) stand at $11.2B, with a total expense ratio of 0.24% per year.
Compared with pure passive vehicles, this ETF adds manager discretion on top of broad diversification, with fine-tuning applied at the individual stock level.
JPMorgan International Research Enhanced Equity ETF Performance and Flows
Flows into developed-market equities outside the US fluctuate with the global business cycle, exchange rates, and regional policy environments, often exhibiting a different cycle from the US market. Research-driven adjustments produce performance patterns that resemble the index while differentiating slightly from it.
Demand for diversification away from the US and interest in low-cost active products underpin the fund's flow trends. Investors seeking to strengthen global diversification tend to use it as a satellite holding to complement their core allocation.
JPMorgan International Research Enhanced Equity ETF Strengths and Weaknesses
Its strengths are low-cost active management and broad developed-market diversification, while the drawbacks include currency exposure and uncertainty around excess returns versus the benchmark.
💪 Key Strengths
⚠️ Points to Watch
JPMorgan International Research Enhanced Equity ETF Alternative ETFs and Related Products
ETFs such as VEA, IEFA, and EFA shown in the table are all passive alternatives that invest in developed markets outside the US and differ in expense ratio and management approach. If you want to broaden exposure to include emerging markets, you can also review VXUS, which covers equities outside the US globally, and VT, a single-fund global equity ETF that includes the US. What distinguishes JIRE is its research-driven active management approach.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| Vanguard FTSE Developed Markets ETF | $68.19 | -3.7% | $233.3B | 0.03% | 2.5% | +12.3% | |
| iShares Core MSCI EAFE ETF | $95.54 | -3.0% | $193.4B | 0.07% | 3.44% | +8.9% | |
| Vanguard Total International Stock ETF | $80.80 | -3.7% | $163.3B | 0.05% | 2.46% | +8.7% | |
| Vanguard Total World Stock ETF | $151.38 | -4.1% | $84.1B | 0.06% | 1.59% | +8.3% | |
| iShares MSCI EAFE ETF | $102.70 | -2.9% | $78.1B | 0.32% | 3.28% | +9.1% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| ASML | ASML Holding NV | 0.07% | $1356.65 | -9.3% | $522.9B | 33.4 | 0.78% |
| AZN | Astrazeneca plc | 0.04% | $186.85 | -1.1% | $289.8B | 26.4 | 1.79% |
| Shell plc ADRhedged | 0.03% | $72.26 | -1.5% | $0.0M | - | 1.69% | |
| HSBC Holdings plc ADRhedged | 0.02% | $97.31 | -1.4% | $0.0M | - | 2.57% | |
| AllianzIM U.S. Equity Buffer100 Protection ETF | 0.02% | $26.39 | -0.4% | $0.0M | - | - | |
| HSBC | HSBC Holdings plc ADR | 0.01% | $88.06 | -1.5% | $301.8B | 11.5 | 4.71% |
| AllianzIM U.S. Equity Buffer20 May ETF | 0.01% | $35.00 | -1.9% | $0.0M | - | - |
Investor Checklist for the JPMorgan International Research Enhanced Equity ETF
Below are the points to review before investing in JIRE. Although it serves as a vehicle for diversification across developed markets outside the US, FX risk, the active management approach, the potential for excess return versus the index, and regional exposure are items that should be confirmed in advance.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 💵 Expense Ratio | Level of fees within the active category | On the lower end |
| 🌍 Regional Exposure | Trends in weights across Europe, Japan, etc. | Developed-market diversification |
| ⚙️ Management Style | Whether it is research-driven active | Beta-neutral active |
| 💱 Currency | Impact on won-denominated returns | Unhedged |
FX moves and regional business-cycle differences are the main drivers of short-term volatility. Even with active management, the fund may not consistently outperform the index, so excess returns are not guaranteed.
For investors seeking diversification across developed-market equities outside the US while targeting a modest research-driven excess return, this ETF is worth considering. If you prefer a pure low-cost passive option, VEA and IEFA are alternatives, and VXUS is an option if you want to extend exposure to emerging markets.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 21, 2026.